Highlights Immunovant, Inc.

Equities

IMVT

US45258J1025

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
28.42 ^USD	-1.83%		-6.20%	-32.54%

May. 24	Immunovant Insider Sold Shares Worth $479,233, According to a Recent SEC Filing	MT
Apr. 20	Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immunovant Posts Narrower Fiscal Q3 Loss	Feb. 12	MT
Immunovant, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 12	CI
North American Morning Briefing : Stock Futures -2-	Feb. 09	DJ
North American Morning Briefing : Jobs Report Tops -2-	Feb. 02	DJ
Immunovant, Inc. Announces Results from the Initial Cohort of Patients in an Ongoing 24-Week Phase 2 Clinical Trial of Batoclimab in Patients with Graves' Disease Meaningfully Exceeded 50% Response Rates	Dec. 20	CI
Immunovant, Inc. Announces Initial Data from 600 Mg MAD Cohort of A Phase 1 Clinical Trial of IMVT-1402 in Healthy Adults	Nov. 28	CI
Immunovant, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 09	CI
Immunovant, Inc. Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results	23-09-26	CI
Immunovant, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10	CI
Immunovant, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-22	CI
Immunovant, Inc. Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-22	CI
Immunovant's Fiscal Q3 Loss Widens	23-02-03	MT
Immunovant, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-03	CI
Immunovant's Fiscal Q2 Loss Widens	22-11-04	MT
Immunovant, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-04	CI
Earnings Flash (IMVT) IMMUNOVANT Posts Q2 Loss $-0.41	22-11-04	MT
Immunovant, Inc. Announces IMVT-1402	22-09-28	CI
Immunovant Plans to Develop Investigational Compound Batoclimab for Two New Target Indications	22-09-07	MT
Immunovant Announces Two New Development Programs for Batoclimab	22-09-07	CI
Immunovant Fiscal Q1 Net Loss Widens; Current Cash Balance Provides Runway Into 2025	22-08-05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Immunovant, Inc.

Equities

IMVT

US45258J1025

Highlights

Filters